BU-NOT-SET

CONTACT US
Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand
  • Drug substance
Eyes
Insight
A CDMO’s insight into the pharma M&A landscape
  • Industry trends
Eyes
Insight
Recipharm’s continuous global support throughout the COVID-19 pandemic
  • Industry trends
Eyes
Insight
Is outsourcing the most viable pathway for innovators?
  • Manufacturing
Meeting
Insight
Developing a generic prolonged-release isosorbide-5-mononitrate tablet
  • Drug product
Two lab workers
Case study
Recipharm Wins two 2020 CMO Leadership Awards
  • Industry trends
Eyes
Insight
Recipharm’s global teams support and engage with their local communities in the fight against COVID-19
  • Corporate
Eyes
Insight
Recipharm launches new virtual inspection and audit tool for customers, in light of COVID-19 outbreak
  • Manufacturing
Eyes
Insight
Recipharm 25 years
  • Corporate
24 years
Brochure
Insight
  • Drug substance
Regulatory requirements for drug substances
Insight
  • Analytical chemistry
The QbD approach: Key advantages in clinical and commercial phases
Report
  • Sustainability
Sustainability report 2020
Poster
  • Drug substance
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
Fact sheet
  • Analytical chemistry
Recipharm Analytical Solutions™
Fact sheet
  • Analytical chemistry
Impurity identification
Fact sheet
  • Analytical chemistry
Stability studies
Fact sheet
  • Analytical chemistry
Extractables & leachables testing
Insight
  • Industry trends
Pharmaceutical mergers and acquisitions: opportunities and drivers for CDMOs